Compare Eli Lilly And Co (LLY) vs Workiva Inc (WK) Price & Performance

Eli Lilly (LLY) trades at $1,223.97, down 0.62% on the day, maintaining strong bullish momentum with consecutive earnings beats and robust revenue growth. The stock shows technical strength above key support levels at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 102.44% ROE. Recent quarterly results exceeded expectations, with Q2 2026 revenue surging 48% to $23 billion driven by Mounjaro and Zepbound demand.

Outlook remains positive with analyst consensus targeting $1,380 and 73% buy ratings, though elevated valuations (P/E 40.8) and regulatory risks around weight-loss drug competition present headwinds. The company's pipeline advancement with retatrutide filing expected in 2027 provides medium-term growth catalysts, but investors should monitor execution risks in the competitive obesity drug market.

Workiva (WK) trades at $68.07, up 1.11% today, with strong technical momentum and bullish moving averages. The company has delivered three consecutive quarterly earnings beats, with Q2 2026 revenue of $255 million exceeding guidance. Analyst sentiment remains overwhelmingly positive with 16 buy ratings and a $69 consensus target. The stock shows robust revenue growth but elevated valuation multiples with a P/E of 82.2.

Outlook remains constructive given consistent earnings outperformance and strong subscription growth, though high valuation and negative net income in 2025 present risks. The company's AI platform expansion and Fortune 500 customer base support long-term growth potential, but investors should monitor profitability improvement and competitive pressures in the compliance software space.